MRNA

Moderna Inc

Add to Watchlist

Advanced Chart

27.775

-0.045(-0.160%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

27.865

Open

27.490

VWAP

27.49

Vol

1.73M

Mkt Cap

10.76B

Low

27.230

Amount

47.50M

EV/EBITDA(TTM)

Total Shares

383.24M

3.65B

EV/OCF(TTM)

P/S(TTM)

3.29

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

115.32M

-30.95%

-3.107

+1.21%

114.08M

-52.66%

-3.115

-6.45%

1.17B

-37.29%

-1.689

-5731.13%

Estimates Revision

The market is revising Downward the revenue expectations for Moderna, Inc. (MRNA) for FY2025, with the revenue forecasts being adjusted by -2.33% over the past three months. During the same period, the stock price has changed by -32.32%.

Revenue Estimates for FY2025

Revise Downward

-2.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+15.59%

In Past 3 Month

Stock Price

Go Down

-32.32%

In Past 3 Month

19 Analyst Rating

74.08% Upside

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 48.35 USD with a low forecast of 23.00 USD and a high forecast of 212.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

13 Hold

4 Sell

Hold

74.08% Upside

Current: 27.775

Low

23.00

Averages

48.35

High

212.00

74.08% Upside

Current: 27.775

Low

23.00

Averages

48.35

High

212.00

Morgan Stanley

Matthew Harrison

Hold

Maintains

$39 → $32

2025-04-09

Reason

Morgan Stanley

Matthew Harrison

Price Target

$39 → $32

2025-04-09

Maintains

Hold

Reason

JP Morgan

Jessica Fye

Sell

Maintains

$40 → $33

2025-03-21

Reason

JP Morgan

Jessica Fye

Price Target

$40 → $33

2025-03-21

Maintains

Sell

Reason

JPMorgan analyst Jessica Fye lowered the firm's price target on Moderna to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza estimates. The firm now models 2025 RSV sales of about $148M, versus a prior estimate of about $210M, and for FY25 it now models total revenue of $2.1B, versus consensus of $2.2B and just above the $2B guidance midpoint, the analyst tells investors.

Citigroup

Geoff Meacham

Hold

Initiates

$40

2025-03-13

Reason

Citigroup

Geoff Meacham

Price Target

$40

2025-03-13

Initiates

Hold

Reason

Citi initiated coverage of Moderna with a Neutral rating and $40 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.

UBS

Eliana Merle

Strong Buy

Maintains

$96 → $78

2025-02-19

Reason

UBS

Eliana Merle

Price Target

$96 → $78

2025-02-19

Maintains

Strong Buy

Reason

Barclays

Gena Wang

Buy

Hold

Downgrades

$111 → $45

2025-02-18

Reason

Barclays

Gena Wang

Price Target

$111 → $45

2025-02-18

Downgrades

Buy

Hold

Reason

RBC Capital

Luca Issi

Hold

Reiterates

$40

2025-02-18

Reason

RBC Capital

Luca Issi

Price Target

$40

2025-02-18

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -2.70, compared to its 5-year average forward P/E of -52.08. For a more detailed relative valuation and DCF analysis to assess Moderna Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-52.08

Current PE

-2.70

Overvalued PE

161.35

Undervalued PE

-265.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

4.60

Current EV/EBITDA

-0.46

Overvalued EV/EBITDA

48.47

Undervalued EV/EBITDA

-39.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.21

Current PS

4.98

Overvalued PS

28.23

Undervalued PS

-7.81